ArticleFrontiers in immunology2026
Superior outcomes with offspring B-leader-matched haploidentical versus older matched sibling donors in AL/MDS patients aged ≥40 years.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With advancing safety profiles in allogeneic hematopoietic stem cell transplantation (allo-HSCT), determining whether HLA-matched siblings remain the optimal donor choice for older adults (≥40 years) and whether haploidentical-HSCT demonstrates superior survival outcomes have become pivotal focuses in transplantation research. Methods: The goal of this study was to explore the efficacy of haploidentical or matched sibling allo-HSCT in patients over the age of 40 years with acute leukemia (AL) and myelodysplastic syndrome (MDS), with a prespecified primary endpoint of GVHD-free, relapse-free survival (GRFS). In this retrospective study, 195 consecutive AL/MDS patients (≥40 years) who received allo-HSCT between December 2014 and December 2023 were included and analyzed using a 1:2 matched-pair design. All patients received antithymocyte globulin (ATG)-based GVHD prophylaxis. The cohort comprised 130 patients with haploidentical donors (HIDs) and 65 with HLA-matched sibling donors (MSDs). Results: Patients who received transplants from offspring haploidentical donors with mismatched DRB1 exhibited a significantly lower 5-year cumulative incidence of relapse (15.4%) than those who received MSDs-HSCT (45.3%) or transplants from offspring haploidentical DRB1-matched donors (26.7%; p < 0.001). However, the 5-year nonrelapse mortality (NRM) was highest in the offspring haploidentical B-leader-mismatched group (43.8%) compared with that in the B-leader-matched group (15.4%) and MSDs group (6.3%). Accordingly, in univariate analysis, recipients of offspring haploidentical B-leader-matched donors exhibited superior OS and DFS compared with recipients of older MSDs or offspring B-leader-mismatched donors; multivariate analysis further identified B-leader matching as an independent protective factor against NRM and an independent factor associated with improved GRFS. Conclusion: In AL/MDS patients aged ≥40 years, offspring haploidentical B-leader-matched donors were associated with favorable survival outcomes compared with older MSDs, primarily driven by reduced NRM; additionally, DRB1 mismatching was independently associated with reduced relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.